Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Use of Extremophile Bacterium XT1 in Biological Approach to Promote Plant Growth and Tackle Pathogens

Ziel

Securing sustainable food production whilst preserving ecosystem services has become imperative following the growing trend of population and the increasing need in environment protection. Traditional agricultural methods are called to introduce changes to meet these challenges.
One of the main threats posed to global food security is plant diseases, commonly treated with chemicals responsible for toxic effects and biodiversity disorders.
The present project proposes XTOnE, an organic alternative to chemicals based on the patented extremophile bacterium XT1, whose innovative concept lies on the unique characteristics of this microorganism. XT1 enables induced mechanisms in plants raising self-defense against external pathogens and stresses, stimulating nutrition efficiency and uptake and improving growth and quality.
The expected outcome is a product that acts contemporarily as biostimulant, biofertiliser and organic pest controller whose benefits on plants are preserved even in extreme conditions.
XTOnE addresses the need of farmers by guaranteeing a plant protection throughout the entire life-cycle and reducing losses. It can be grown into organic wastes allowing the reuse of leftovers and unlocking the agriculture potential in delivering the objectives of the Circular Economy.
Its first application will be against a worldwide fungal disease, Verticillium, attacking more than 200 species and affecting especially Europe. XTOnE raised the interest of companies with a European and International presence, due to the lacking of similar solution. Thanks to its easy-of-use and affordable price, it projected to have European and global commercial potential.
In the Feasibility Study, Xtrem Biotech aims to assess the end users’ requirements and the innovation’s economic benefits. The best regulatory and protection roadmap will be defined together with the associated activities to be developed through a potential Phase 2 funding for ensuring the commercialization.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

SME-1 - SME instrument phase 1

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) H2020-SMEInst-2016-2017

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

XTREM BIOTECH SL
Netto-EU-Beitrag
€ 50 000,00
Adresse
AVENIDA DEL CONOCIMIENTO 1 EDIFICIO BIC ESC 4 PLANTA 1 PUERTA A
18016 GRANADA
Spanien
KMU
Ja
Region
Sur Andalucía Granada
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 71 429,00